A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 142
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : SSRIs
Long Form : serotonin selective reuptake inhibitors
No. Year Title Co-occurring Abbreviation
2019 Loss of Adult 5-HT1A Autoreceptors Results in a Paradoxical Anxiogenic Response to Antidepressant Treatment. FLX, KO, WT
2019 Multifaceted Regulations of the Serotonin Transporter: Impact on Antidepressant Response. CNS, TMDs
2018 Abnormal Serotonin Levels During Perinatal Development Lead to Behavioral Deficits in Adulthood. ---
2018 Association of Depression and Cervical Spondylosis: A Nationwide Retrospective Propensity Score-Matched Cohort Study. aHR, CI
2018 Fatal intoxication with antidepressants: a case with many culprits. MAO
2018 Prolonged therapy with antidepressants increases hippocampal level of kynurenic acid and expression of Kat1 and Kat2 genes. KYNA, TCAs
2018 Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer's Disease Patients with Depressive Symptoms. AD, MCI, SUVRWM
2018 Serotonin Selective Reuptake Inhibitors (SSRIs) and Female Sexual Dysfunction (FSD): Hypothesis on its Association and Options of Treatment. FSD, NO
2018 Serotonin Selective Reuptake Inhibitors (SSRIs) and Stroke. ---
10  2017 A comparative QSAR analysis and molecular docking studies of phenyl piperidine derivatives as potent dual NK1R antagonists/serotonin transporter (SERT) inhibitors. FA-MLR, MLR, NK1R, PCR, QSAR, SERT
11  2017 Regulation of Bone Metabolism by Serotonin. SERT
12  2017 Serotonergic 5HTTLPR/rs25531 s-allele homozygosity associates with violent suicides in male citalopram users. ---
13  2016 Cortico-striato-thalamo-cortical circuit abnormalities in obsessive-compulsive disorder: A voxel-based morphometric and fMRI study of the whole brain. fMRI, MRI, OCD, VBM
14  2016 Discovery of Indazoles as Potent, Orally Active Dual Neurokinin 1 Receptor Antagonists and Serotonin Transporter Inhibitors for the Treatment of Depression. NK-1, SERT
15  2016 Donepezil as Add-on Treatment for Resistant Obsessive-Compulsive Disorder: Retrospective Case Series. OCD
16  2016 Pharmacogenetics of citalopram-related side effects in children with depression and/or anxiety disorders. AD, MDD, SE
17  2015 Biaryls as potent, tunable dual neurokinin 1 receptor antagonists and serotonin transporter inhibitors. NK1R, SERT
18  2015 Fluoxetine-induced transactivation of the platelet-derived growth factor type beta receptor reveals a novel heterologous desensitization process. GPCRs, PDGF, PDGF, RTKs
19  2015 Pregabalin versus sertraline in generalized anxiety disorder. An open label study. CGI, GAD, HAM-A, NICE, SNRIs, WFSBP
20  2015 SSRI use during pregnancy. ---
21  2014 Fluoxetine and all other SSRIs are 5-HT2B Agonists - Importance for their Therapeutic Effects. SERT
22  2014 Ondansetron reduces naturalistic drinking in nontreatment-seeking alcohol-dependent individuals with the LL 5'-HTTLPR genotype: a laboratory study. AD, ASAE
23  2014 Protein-drug interactome analysis of SSRI-mediated neurorecovery following stroke. GO, MD, NOTCH1, PDI, ROCK1
24  2014 Successful treatment of relapsed Meniere's disease using selective serotonin reuptake inhibitors: A report of three cases. CSD, EDS, MAV
25  2014 Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats. CIC
26  2013 Danish physicians' preferences for prescribing escitalopram over citalopram and sertraline to treatment-naive patients: a national, register-based study. ---
27  2013 Pharmacologic treatment of sex offenders with paraphilic disorder. ---
28  2013 The effect of antidepressant drugs on thioacetamide-induced oxidative stress. ALP, AST, MDA
29  2012 GTP cyclohydrolase 1 gene haplotypes as predictors of SSRI response in Japanese patients with major depressive disorder. BP, MDD, MDs, SIGH-D
30  2012 Identification of the cortical neurons that mediate antidepressant responses. ---
31  2012 In right or biventricular chronic heart failure addition of thiazides to loop diuretics to achieve a sequential blockade of the nephron is associated with increased risk of dilutional hyponatremia: results of a case-control study. AVP, CHF
32  2012 Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression. ECT, MAOA, MAOIs, RIMAs, RIMAs, TRD
33  2012 Temperament profiles, major depression, and response to treatment with SSRIs in psychiatric outpatients. HA, MADRS, MDD, RD, TCI
34  2012 The association between sunshine duration and paroxetine response time in patients with major depressive disorder. ERs, LRs, MADRS, NRs, UERs
35  2011 Depression treatment and maternal functioning. MDD
36  2011 Effects of chronic treatment with fluoxetine on receptor-stimulated increase of [Ca2+]i in astrocytes mimic those of acute inhibition of TRPC1 channel activity. RyR
37  2011 Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice. FST, MBB
38  2011 New treatment options for panic disorder: clinical trials from 2000 to 2010. PD, SNRIs
39  2011 The effect of different antidepressant drugs on oxidative stress after lipopolysaccharide administration in mice. i.p, LPS, TCA
40  2011 The Mechanism of Drug-induced Akathsia. ---
41  2011 [Possibilities and limitations of psychopharmacological treatments in patients with psychological comorbidity]. ---
42  2010 Changes in Cerebral Cortex and Limbic Brain Functions after Short-Term Paroxetine Treatment in Panic Disorder: An [F]FDG-PET Pilot Study. CGI-S, FDG-PET, HAM-A, PD, PDSS
43  2009 Citalopram enhances cocaine's subjective effects in rats. ---
44  2009 GABA transporter lysine 448: a key residue for tricyclic antidepressants interaction. GABA, TCAs
45  2009 Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. CI, NSAID, OR, PPIs, UGIB
46  2008 Case report: a case of intractable Meniere's disease treated with autogenic training. AT, CBT
47  2008 Clinical experience using appetite suppressants and SSRIs. ---
48  2008 Serotonin transporter transgenic (SERTcre) mouse line reveals developmental targets of serotonin specific reuptake inhibitors (SSRIs). SERTcre
49  2008 [Clinical and therapeutic particularities of depression in the elderly]. TCAs
50  2007 Bipolar co-morbidity in pediatric obsessive-compulsive disorder: clinical and treatment implications. ADHD, BD, CD, GAD, OCD, ODD
51  2007 Fluoxetine in posttraumatic eating disorder in two-year-old twins. ---
52  2007 The Cape Town Consensus Statement on obsessive-compulsive disorder. CBT, OCD
53  2006 Ejaculatory dysfunction and depression: pharmacological and psychobiological interactions. ---
54  2006 From selective to highly selective SSRIs: a comparison of the antinociceptive properties of fluoxetine, fluvoxamine, citalopram and escitalopram. ---
55  2006 Investigation of the SSRI augmentation properties of 5-HT(2) receptor antagonists using in vivo microdialysis. 5-HT
56  2005 A population-based assessment of the potential interaction between serotonin-specific reuptake inhibitors and digoxin. CI, OR
57  2005 Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. PD
58  2005 Approach to novel functional foods for stress control 4. Regulation of serotonin transporter by food factors. CNS, SERTs
59  2005 Brainstem levels of transcription factor AP-2 in rat are changed after treatment with phenelzine, but not with citalopram. MAOIs, TCAs
60  2005 Fluoxetine treatment of prepubescent rats produces a selective functional reduction in the 5-HT2A receptor-mediated stimulation of oxytocin. ---
61  2005 Fluoxetine-induced changes in tactile sensation and sexual functioning among clinically depressed women. ---
62  2005 Paroxetine is effective in desensitizing 5-HT1A receptor function in adult offspring exposed prenatally to cocaine. ACTH
63  2004 Aeromedical regulation of aviators using selective serotonin reuptake inhibitors for depressive disorders. AsMA, CAs
64  2004 Pharmacological approaches in the treatment of binge eating disorder. BED
65  2004 Use of antidepressant medications: are there differences in psychiatric visits among patient treatments in the Veterans Administration? SNRIs, TCAs, VA
66  2003 Dual monoamine modulation for improved treatment of major depressive disorder. TCA
67  2003 Indications for and use of antidepressants in child and adolescent psychiatry--a cross-sectional survey in Denmark. ---
68  2001 A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. FQ, PASS, PD, SDS
69  2001 An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. ---
70  2001 Antinociceptive efficacy of antidepressants: assessment of five antidepressants and four monoamine receptors in rats. TCAs
71  2001 Citalopram for social phobia: a clinical case series. ---
72  2001 Diagnosing and treating depression in the elderly. MAOIs, TCAs
73  2001 The effects of inositol treatment in animal models of psychiatric disorders. OCD
74  2000 Antidepressant-induced regulation of 5-HT(1b) mRNA in rat dorsal raphe nucleus reverses rapidly after drug discontinuation. DRN
75  2000 Serotonin discontinuation syndrome: does it really exist? ---
76  1999 Hair loss associated with paroxetine treatment: a case report. ---
77  1999 Psychopharmacotherapy in children and adults with intellectual disability. ---
78  1999 Psychotropic drugs in mothers' milk: a comprehensive review of assay methods, pharmacokinetics and of safety of breast-feeding. ---
79  1999 Serotonin, cerebral blood flow, and cerebral metabolic rate in geriatric major depression and normal aging. MDD, rCBF
80  1999 The treatment of kleptomania with serotonin reuptake inhibitors. ---
81  1998 Antidepressant-induced sexual dysfunction. ---
82  1998 Augmentation strategies with serotonergic-noradrenergic combinations. ---
83  1998 Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action. MAOIs, TCAs
84  1998 Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial. CGI
85  1998 Lithium augmentation of antidepressants in treatment-refractory depression. TCAs
86  1998 Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. ---
87  1998 Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. ---
88  1998 Monoamine dysfunction and the pathophysiology and treatment of depression. AMPT, CNS
89  1998 Noradrenergic versus serotonergic antidepressants: predictors of treatment response. TCAs
90  1998 Reboxetine versus fluoxetine: an overview of efficacy and tolerability. ---
91  1998 Sumatriptan contraindications and the serotonin syndrome. MAOIs
92  1998 The use of antidepressant drugs in patients with heart disease. TCAs
93  1998 The Use of Ginseng as an Adjunct in Treatment-Resistant Depression. TCAs
94  1997 A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. HAM-D
95  1997 Antidepressant discontinuation: a review of the literature. MAOIs, TCAs
96  1997 Antidepressants in panic disorder. MAOIs
97  1997 Biological therapies for posttraumatic stress disorder: an overview. MAOIs, PTSD
98  1997 Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression. ---
99  1997 Development of new antidepressants. ---
100  1997 Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. RCTs